
Daniele Martinelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/648716/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia, 2020, 40, 1026-1044.	3.9	105
2	A Machine Learning Approach for the Differential Diagnosis of Alzheimer and Vascular Dementia Fed by MRI Selected Features. Frontiers in Neuroinformatics, 2020, 14, 25.	2.5	70
3	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 155-164.	10.2	63
4	MRI signatures of the frontotemporal lobar degeneration continuum. Human Brain Mapping, 2015, 36, 2602-2614.	3.6	39
5	Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. Journal of Headache and Pain, 2021, 22, 114.	6.0	31
6	Peripheral vagal nerve stimulation modulates the nociceptive withdrawal reflex in healthy subjects: A randomized, cross-over, sham-controlled study. Cephalalgia, 2018, 38, 1658-1664.	3.9	19
7	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. Cephalalgia, 2021, 41, 1135-1151.	3.9	19
8	Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study. Cephalalgia, 2020, 40, 1336-1345.	3.9	14
9	Thalamocortical Connectivity in Experimentally-Induced Migraine Attacks: A Pilot Study. Brain Sciences, 2021, 11, 165.	2.3	13
10	Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. Journal of Neurology, 2018, 265, 2927-2933.	3.6	12
11	Chronic migraine and Botulinum Toxin Type A: Where do paths cross?. Toxicon, 2020, 178, 69-76.	1.6	12
12	Botulinum toxin for chronic migraine: Clinical trials and technical aspects. Toxicon, 2018, 147, 111-115.	1.6	9
13	Migraine neuroscience: from experimental models to target therapy. Neurological Sciences, 2020, 41, 351-361.	1.9	7
14	BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm. Cephalalgia, 2022, 42, 170-175.	3.9	7
15	Lasmiditan: an additional therapeutic option for the acute treatment of migraine. Expert Review of Neurotherapeutics, 2021, 21, 491-502.	2.8	6
16	Limitations in daily activities and general perception of quality of life: Long term followâ€up in patients with antiâ€myelinâ€glycoprotein antibody polyneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 276-282.	3.1	5
17	Frontal and Cerebellar Atrophy Supports FTSD-ALS Clinical Continuum. Frontiers in Aging Neuroscience, 2020, 12, 593526.	3.4	5
18	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia, 2019, 39, 1058-1066.	3.9	4

0

#	Article	IF	CITATIONS
19	Noninvasive peripheral vagal nerve stimulation prevents migraine aura: A case report. Cephalalgia Reports, 2019, 2, 251581631985560.	0.7	1

20 Headache and the Heart. , 2019, , 1-11.